

Rockville, MD 20857, Phone: (215) 861-4385, or Email: [MFountain@hrsa.gov](mailto:MFountain@hrsa.gov).

#### SUPPLEMENTARY INFORMATION:

*Intended Recipient of Award:*  
Education Development Center, Inc.

*Amount of Non-Competitive Award:*  
Approximately \$330,000/year for FY 2020, FY 2021, and FY 2022.

*Budget Period:* 09/01/2019–08/31/2020; 09/01/2020–08/31/2021; 09/01/2021–08/31/2022.

*CFDA Number:* 93.110.

*Authority:* Social Security Act, Title V, § 511 (42 U.S.C. 711).

*Justification:* The MIECHV Program, an evidence-based home visiting program, seeks to improve maternal and child health outcomes and address various social determinants that impact health equity such as reducing child abuse and neglect, addressing family violence, promoting child development and school readiness, and improving family economic self-sufficiency for families considered most at-risk. In support of HRSA's FY 2019–FY 2022 Strategic Goals focused on health equity, the MIECHV Program proposes to develop a home visiting specific

health equity framework utilizing quality improvement as a methodology.

The HVCoin 2.0 is designed to facilitate the delivery and accelerate the improvement of home visiting services provided by MIECHV Program recipients, including subrecipient local implementing agencies (LIAs) utilizing continuous quality improvement methodologies. The Coin provides a platform and strategy for collaborative learning and quality improvement toward common measurable aims—rapid-cycle tests of change ideas.

The HVCoin has three main priority areas. Priority Area #2 is focused on “testing of new change ideas.” This priority area is designed to develop and subsequently refine discrete sets of change ideas based on evidence in the field and relevance to home visiting implementation. The grantee will carry out all the activities pertaining to the development of the health equity framework. Proposed activities will include:

- Identify a health equity framework and adapt for MIECHV;
- Develop theory of change, (how and why the desired change is expected to happen); key driver diagrams, (the

relationship between the overall aim of the project, the drivers that contribute directly to the aim) change ideas, measures and proposed tests of change;

- Implement a quality improvement strategy such as: Breakthrough Series, Plan-Do-Study-Act Cycles, to test and eventually demonstrate improvements in program outcomes through a health equity collaborative; and pilot test with MIECHV awardees over 12–18 months;

- Apply the health equity framework that demonstrated improvements to twelve current HV Coin 2.0 scale topics (developmental screening, breastfeeding, and maternal depression) and new topic Coins (intimate partner violence and well child care); and

- Create a final health equity Coin playbook with measures, refined tests of change that can be used to spread lessons learned across home visiting programs. EDC was awarded a 5-year HV Coin cooperative agreement on September 1, 2017. They have successfully led the first national effort utilizing CQI methods to assist awardees in improving MIECHV Program implementation, performance measures and evidence based maternal and child health outcomes.

Grantee/organization name	Grant No.	State	FY 2020 funding	FY 2021 funding	FY 2022 funding
Education Development Center, Inc .....	UF4MC26525	MA	\$328,797	\$329,980	\$324,637

Thomas J. Engels,  
Administrator.

[FR Doc. 2020–13338 Filed 6–19–20; 8:45 am]

BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Patient-Oriented Research Review Committee.

*Date:* July 23–24, 2020.

*Time:* 11:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health (NIH), One Rockledge Center, 6705 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Stephanie Johnson Webb, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208–V, Bethesda, MD 20892, (301) 827–7992, [stephanie.webb@nih.gov](mailto:stephanie.webb@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: June 16, 2020.

**Ronald J. Livingston, Jr.,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–13319 Filed 6–19–20; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; “Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19).”

Date: July 15, 2020.

Time: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1206, Bethesda, MD 20892 (Teleconference).

Contact Person: John C. Pugh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1206, Bethesda, MD 20892, (301) 435-2398, [pughjohn@csr.nih.gov](mailto:pughjohn@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: June 16, 2020.

**Tyeshia M. Roberson,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-13324 Filed 6-19-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Ointment for the Topical Administration to Ischemic Treat and/or Neuropathic Ulcers in Humans

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Emmaus Medical Inc. located in 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, 90503.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 7, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Edward Fenn, Senior Licensing and Patenting Manager, NCI Technology Transfer Center, Telephone: 240-276-6833 or Email: [Tedd.Fenn@nih.gov](mailto:Tedd.Fenn@nih.gov).

**SUPPLEMENTARY INFORMATION:**

### Intellectual Property

I. United States Provisional Patent Application No. 62/077,622 filed Nov. 10, 2014, "Topical Sodium Nitrite Formulations", [HHS Ref. No. E-149-2014-0-US-01];

II. International Patent Application No. PCT/US2015/060015 filed Nov. 10, 2015, "Topical Sodium Nitrite Formulations", [HHS Reference No. E-149-2014-0-PCT-02];

III. European National Stage Patent Application No. 15798623.3, filed Nov. 10, 2015, "Topical Sodium Nitrite Formulations", [HHS Ref. No. E-149-2014-0-EP-03];

IV. U.S. National Stage Patent Application No. 15/525,557 filed May 9, 2017, "Topical Sodium Nitrite Formulations", [HHS Ref. No. E-149-2014-0-US-04];

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be the United States only and the field of use may be limited to the following:

"Treatment of neuropathic and/or ischemic skin ulcers in humans".

This technology discloses a topical ointment formulation comprising about .5% to 3.0% by weight non-acidified sodium nitrite dispersed in white petrolatum, mineral oil and bisabolol for topical administration. Nitrite anions may act as a vasodilator in vivo by generating nitric oxide (NO) in tissues with lower oxygen tension and pH. Therapeutic application of sodium nitrite through this specific topical formulation may provide selective vasodilation to hypoxemic tissue that treat ulcers associated with chronic ischemic and neuropathic ulcer conditions associated with several diseases.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license

applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: June 12, 2020.

**Richard U. Rodriguez,**

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2020-13315 Filed 6-19-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Opportunities for Collaborative Research at the NIH Clinical Center.

*Date:* July 23, 2020.

*Time:* 12:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* YingYing Li-Smerin, MD, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 207-P, Bethesda, MD 20892-7924, (301) 827-7942, [lismerein@nhlbi.nih.gov](mailto:lismerein@nhlbi.nih.gov).

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Grant Review for NHLBI K Award Recipients.

*Date:* July 24, 2020.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20814 (Telephone Conference Call).

*Contact Person:* Michael P Reilly, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7975, [reillymp@nhlbi.nih.gov](mailto:reillymp@nhlbi.nih.gov).